AOD-9604

weak data

Also seen as: AOD, anti-obesity drug 9604

The Dose Guy’s verdict

Sep 1, 2026
2 sources

Skip it. AOD-9604 went to human trials for obesity, produced nothing worth publishing, and the developer walked away. No phase 3 happened, no efficacy data was ever released, and the compound quietly died in development in the mid-2000s. Vendors kept selling it anyway because the peptide market does not require an FDA gatekeeper, and the pitch, “the fat-burning fragment of growth hormone without the growth effects,” sounds too clean to fact-check. I did. The answer is no.

Would I take it?No, it already failed.

What it is

A synthetic peptide made from the tail end of human growth hormone, amino acids 177 through 191 plus a tyrosine. If you have seen HGH fragment 176-191 sold online, AOD-9604 is the modified version of the same sequence. Both were designed to keep the lipolytic activity of HGH while dropping the growth and blood-sugar effects. In rodents it worked: obese mice gained less weight, obese rats cut weight gain in half, and neither species showed the insulin problems that full HGH causes. Chronic dosing restored beta-3 adrenergic receptor expression in fat tissue, but acutely AOD-9604 raised energy expenditure and fat oxidation even in mice that lacked the beta-3 receptor entirely, so the mechanism is not as simple as one switch.

The translation to humans failed. A development company took AOD-9604 through phase 2a, published nothing, and by 2006 a review of anti-obesity drugs noted that among the candidates it covered, only rimonabant had completed phase 3. The vendor market picked up where the drug company left off, and AOD-9604 has been sold continuously ever since on a shelf now dominated by compounds like retatrutide and semaglutide that actually cleared their human programs.

What the research shows

No human trials. Zero. Everything below is animal or in-vitro work. Read it as “interesting,” not “evidence it works in you.”

The animal data is clean. The human chapter is an absence:

In obese Zucker rats, oral AOD-9604 at 500 micrograms per kg daily for 19 days reduced weight gain by more than 50%, 15.8 g versus 35.6 g in controls, without impairing insulin sensitivity.Horm Res 2000 · rat study

By February 2002, AOD-9604 was in phase 2a development as an anti-obesity treatment.2004 · development review

No published randomized human efficacy results for AOD-9604 in obesity exist. The compound entered human trials and no data came out. That silence is the result.as of Aug 2026

Realistic protocols

The drug failed in human trials for the thing people buy it for. I am not writing a protocol for a compound whose own developers abandoned it after the human data came back.

For the record, the vendor-market protocol is 250 to 300 mcg injected subcutaneously daily, typically on an empty stomach, for 8 to 12 weeks. That protocol was built by the peptide sales community, not by anyone with access to the unpublished trial data. Nobody knows if it approximates the doses the trials used, because those doses were never published either.

The money is better spent on the compounds at the top of this shelf that have published human results showing they work.

Side effects

No published human safety data. Everything here is animal data or user reports:

anecdotalInjection-site irritation, mild water retention, and occasional headache, all from user reports with no controlled denominator.

monitorBlood sugar is worth watching on any growth-hormone-related peptide, though AOD-9604 was specifically designed to avoid that effect, and the rodent data showed no hyperglycemia.

unknownNo human safety data has been published. A compound that went to human trials with no published results leaves you guessing whether the silence was about efficacy, safety, or both.